Abstract
Background In patients with chronic coronary syndromes (CCS) increased ventilation/carbon dioxide production (V̇E/V̇CO2) slope has been found to predict disease progression and mortality similarly to patients with heart failure (HF), however, chemosensitivity has rarely been assessed in patients with CCS.
Method Patients with CCS, HF with reduced ejection fraction (EF<50%), old healthy (45+ years) and young adult healthy controls (<35 years) were recruited. For patients, a V̇E/V̇CO2 slope ≥36 was an inclusion criterion. The Duffin rebreathing method was used to determine the resting end-expiratory partial pressure of carbon dioxide (PETCO2), ventilatory recruitment threshold (VRT) and slope (sensitivity) during a hyperoxic (150 mmHg O2) and hypoxic (50 mmHg O2) rebreathing test to determine central and peripheral chemosensitivity.
Results In patients with CCS, HF, and old and young controls, median V̇E/V̇CO2 slopes were 40.2, 41.3, 30.5 and 28.0, respectively. Both patient groups had similarly reduced hyperoxic VRT (at PETCO2 42.1 and 43.2 mmHg) compared to 46.0 and 48.8 mmHg in the old and young controls. Neither hypoxic VRT nor hyper- or hypoxic slopes were significantly different in patients compared to controls. Both patient groups had lower resting PETCO2 than controls, but only patients with HF had increased breathing frequency and rapid shallow breathing at rest.
Conclusion In patients with cardiac disease and excess ventilation, central chemoreflex VRT was reduced independently of the presence of heart failure. Low VRTs were related to resting excess ventilation in patients with CCS or HF, however, rapid shallow breathing was present only in patients with HF.
What is new?
Excess ventilation during exercise and heightened chemosensory reflexes may be present not only in patients with HF but also in patients with CCS. This suggests that there is a gradual derangement of neurologic and/or hormonal factors leading to excess ventilation before the establishment of HF.
In patients with excess ventilation during exercise there is also excess ventilation at rest.
Excess ventilation in patients with CCS does not show the rapid shallow breathing pattern that is typical for patients with HF.
What are the clinical implications?
While excess ventilation during exercise causes dyspnoea with associated negative effects on exercise tolerance and quality of life,1 excess ventilation at rest has been poorly investigated. More research is warranted as physiologic consequences may be substantial with the large time spent at rest compared to exercise.
The finding that the threshold of PETCO2 at which ventilation starts to increase rather than the V̇E/PETCO2 slope is increased in patients with inefficient ventilation suggests electrolyte derangement as an at least contributing cause which may stimulate alternative treatments such as intravenous iron therapy.2
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05057884
Funding Statement
There was no funding for the present study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethikkommission des Kt. Bern
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Original coded data will be made available upon direct request to the corresponding author.
